APA

Van Cutsem E., Prenen H., D'Haens G., Bennouna J., Carrato A., Ducreux M., Bouché O., Sobrero A., Latini L., Staines H., Oum'Hamed Z., Dressler H., Studeny M. & Capdevila J. (20160707). A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Van Cutsem E, Prenen H, D'Haens G, Bennouna J, Carrato A, Ducreux M, Bouché O, Sobrero A, Latini L, Staines H, Oum'Hamed Z, Dressler H, Studeny M and Capdevila J. 20160707. A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Van Cutsem E., Prenen H., D'Haens G., Bennouna J., Carrato A., Ducreux M., Bouché O., Sobrero A., Latini L., Staines H., Oum'Hamed Z., Dressler H., Studeny M. and Capdevila J. (20160707). A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Van Cutsem E, Prenen H, D'Haens G, Bennouna J, Carrato A, Ducreux M, Bouché O, Sobrero A, Latini L, Staines H, Oum'Hamed Z, Dressler H, Studeny M and Capdevila J. A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. : Annals of oncology : official journal of the European Society for Medical Oncology. 20160707.